Brief Reports
Copyright ©The Author(s) 2001. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2001; 7(5): 722-725
Published online Oct 15, 2001. doi: 10.3748/wjg.v7.i5.722
p16 gene methylation in colorectal cancers associated with Duke′s staging
Jing Yi, Zhi-Wei Wang, Hui Cang, Yu-Ying Chen, Ren Zhao, Bao-Ming Yu, Xue-Ming Tang
Jing Yi, Zhi-Wei Wang, Hui Cang, Yu-Ying Chen, Xue-Ming Tang, Department of Cell Biology, Shanghai 200025, China
Ren Zhao, Bao-Ming Yu, Department of Surgery, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
Author contributions: All authors contributed equally to the work.
Supported by the grants from Ministry of Public Health of China, No.98-1-303 and The Educational Committee of Shanghai, No.2000B02.
Correspondence to: Dr. Jing Yi, Department of Cell Biology, Shanghai Second Medical University, 280 Chongqing South Road, Shanghai 200025, China.
Received: April 11, 2001
Revised: June 6, 2001
Accepted: June 20, 2001
Published online: October 15, 2001

AIM: To explore the association of methylation of the CpG island in the promotor of the P16 tumor suppressor gene with the clinicopathological characteristics of the colorectal cancers.

METHODS: Methylation-specific PCR (MSP) was used to detect P16 methylation of 62 sporadic colorectal cancer specimens.

RESULTS: P16 methylation was detected in 42% of the tumors. Dukes’ staging was associated with P16 methylation status. p16 methylation occurred more frequently in Dukes’ C and D patients (75.9%) than in Dukes’ A and B patients (12.1%).

CONCLUSION: P16 methylation plays a role in the carcinogenes is of a subset of colorectal cancer, and it might be linked to poor prognosis.

Keywords: colorectal neoplasma/pathology, genes, P16, polymerase chain reaction/METHODS, CpG region, methylation, MSP